CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Shree Ganesh Remedies Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Shree Ganesh Remedies Ltd
Plot no-6011,G.I.D.C Estate
Phone: +91 2646227777p:+91 2646227777 ANKLESHWAR, 393002  India Ticker: 540737540737
Business Summary
Shree Ganesh Remedies Limited is an India-based company, which is engaged in the business of bulk drug intermediates. The Company's products include intermediates by active pharmaceutical ingredient (API), and fine and specialty chemicals. Its human health API intermediates include antipsychotic, antidepression, oncology, diabetic, and diuretic. Its specialty & fine chemicals include aroma & health industry, agro-industry, polymer industry, and electronics industry. Its veterinary API intermediates include feed additives, antiparasitic, and anti-inflammatory. Its anti-arrhythmic API intermediates include amiodarone intermediates, dronedarone intermediates, and mesalazine intermediates. Its anti-cancer API intermediates include cabozantinib intermediates, gefitinib intermediates, olaparib intermediates, and raloxifene intermediates. Its anti-parasitic API intermediates include flubendazole intermediates, nitazoxanide intermediates, and praziquantel intermediates.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/20243/31/2024Yes----

Industries
SIC Code Description
8731 Commercial physical and biological research
2834 Pharmaceutical preparations
2899 Chemicals and chemical preparations, not elsewhere classified

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, Managing Director Chandulal M.Kothia 59 4/27/1995 4/27/1995
Whole-Time Director Gunjan C.Kothia 29 8/21/2020 4/15/2020
Additional Whole-Time Director Parth C.Kothia 25 1/18/2021 1/18/2021
5 additional Officers and Directors records available in full report.

Business Names
Business Name
540737
890181

General Information
Number of Employees: 139 (As of 3/31/2024)
Outstanding Shares: 12,837,620 (As of 12/31/2024)
Shareholders: 6,814
Stock Exchange: BOM
Fax Number: +91 2646226422


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, January 29, 2025